GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Center Laboratories Inc (ROCO:4123) » Definitions » EBIT

Center Laboratories (ROCO:4123) EBIT : NT$-161 Mil (TTM As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Center Laboratories EBIT?

Center Laboratories's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was NT$474 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was NT$-161 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Center Laboratories's annualized ROC % for the quarter that ended in Sep. 2024 was 0.71%. Center Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 136.07%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Center Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -0.47%.


Center Laboratories EBIT Historical Data

The historical data trend for Center Laboratories's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Center Laboratories EBIT Chart

Center Laboratories Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 207.88 6,080.69 2,698.39 -506.22 -913.73

Center Laboratories Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,053.03 -41.24 -526.22 -67.73 473.99

Competitive Comparison of Center Laboratories's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Center Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Center Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Center Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Center Laboratories's EV-to-EBIT falls into.



Center Laboratories EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-161 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Center Laboratories  (ROCO:4123) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Center Laboratories's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=260.272 * ( 1 - 33.95% )/( (22517.795 + 25687.65)/ 2 )
=171.909656/24102.7225
=0.71 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=27049.569 - 1627.718 - ( 3890.574 - max(0, 2392.353 - 5296.409+3890.574))
=22517.795

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=26027.63 - 484.367 - ( 3303.491 - max(0, 3976.857 - 3832.47+3303.491))
=25687.65

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Center Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1895.964/( ( (1362.884 + max(-1273.569, 0)) + (1423.786 + max(-194.323, 0)) )/ 2 )
=1895.964/( ( 1362.884 + 1423.786 )/ 2 )
=1895.964/1393.335
=136.07 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(186.434 + 272.677 + 40.328) - (1627.718 + 0 + 145.29)
=-1273.569

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(172.742 + 298.625 + 26.722) - (484.367 + 0 + 208.045)
=-194.323

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Center Laboratories's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-161.197/34231.966
=-0.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Center Laboratories EBIT Related Terms

Thank you for viewing the detailed overview of Center Laboratories's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Center Laboratories Business Description

Traded in Other Exchanges
N/A
Address
No. 3-2, Park Street, 7th floor, Nangang District, Taipei, TWN
Center Laboratories Inc is active in the healthcare sector. The company is engaged in the manufacture and sale of various Western medicines. The segments include: Pharmaceutical Division which includes manufacturing and sales of various Western Medicines; Biotechnology Venture Capital consists Investing in domestic and foreign biotechnology undertakings; Glac segment - Manufacture and sale of probiotic products and others. It geographically operates in Taiwan, China and Others.

Center Laboratories Headlines

No Headlines